NCT02988843 2020-12-10Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell TumorsMasonic Cancer Center, University of MinnesotaPhase 2 Terminated1 enrolled 8 charts
NCT02689219 2019-12-10Brentuximab Vedotin in Relapsed/Refractory Germ Cell TumorsIndiana UniversityPhase 2 Terminated18 enrolled 13 charts